3 false false false false false false false false false false true false false false false false true No description of principal activity 2023-07-01 Sage Accounts Production Advanced 2023 - FRS102_2023 913 1,974 xbrli:pure xbrli:shares iso4217:GBP 06279987 2023-07-01 2024-06-30 06279987 2024-06-30 06279987 2023-06-30 06279987 2022-06-30 2023-06-30 06279987 2023-06-30 06279987 2022-06-29 06279987 bus:RegisteredOffice 2023-07-01 2024-06-30 06279987 bus:Director1 2023-07-01 2024-06-30 06279987 bus:Director2 2023-07-01 2024-06-30 06279987 bus:Director3 2023-07-01 2024-06-30 06279987 core:WithinOneYear 2024-06-30 06279987 core:WithinOneYear 2023-06-30 06279987 core:RetainedEarningsAccumulatedLosses 2023-06-30 06279987 core:RetainedEarningsAccumulatedLosses 2022-06-29 06279987 core:RetainedEarningsAccumulatedLosses 2024-06-30 06279987 core:RetainedEarningsAccumulatedLosses 2023-06-30 06279987 core:ShareCapital 2024-06-30 06279987 core:ShareCapital 2023-06-30 06279987 core:SharePremium 2024-06-30 06279987 core:SharePremium 2023-06-30 06279987 bus:SmallEntities 2023-07-01 2024-06-30 06279987 bus:AuditExempt-NoAccountantsReport 2023-07-01 2024-06-30 06279987 bus:SmallCompaniesRegimeForAccounts 2023-07-01 2024-06-30 06279987 bus:PrivateLimitedCompanyLtd 2023-07-01 2024-06-30 06279987 bus:FullAccounts 2023-07-01 2024-06-30
COMPANY REGISTRATION NUMBER: 06279987
IOTA Pharmaceuticals Limited
Unaudited Financial Statements
30 June 2024
IOTA Pharmaceuticals Limited
Financial Statements
Year ended 30 June 2024
Contents
Page
Directors' report
1
Statement of income and retained earnings
2
Statement of financial position
3
Notes to the financial statements
4
IOTA Pharmaceuticals Limited
Directors' Report
Year ended 30 June 2024
The directors present their report and the unaudited financial statements of the company for the year ended 30 June 2024 .
Directors
The directors who served the company during the year were as follows:
D Bailey
S Boyd
P England
Small company provisions
This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.
This report was approved by the board of directors on 4 December 2024 and signed on behalf of the board by:
D Bailey
P England
Director
Director
Registered office:
St Johns Innovation Centre
Cowley Road
Cambridge
Cambridgeshire
United Kingdom
CB40WS
IOTA Pharmaceuticals Limited
Statement of Income and Retained Earnings
Year ended 30 June 2024
2024
2023
Note
£
£
Administrative expenses
11,913
1,974
Other operating income
11,000
--------
-------
Operating loss
( 913)
( 1,974)
--------
-------
Loss before taxation
( 913)
( 1,974)
Tax on loss
----
-------
Loss for the financial year and total comprehensive income
( 913)
( 1,974)
----
-------
Retained losses at the start of the year
( 63,871)
( 61,897)
--------
--------
Retained losses at the end of the year
( 64,784)
( 63,871)
--------
--------
All the activities of the company are from continuing operations.
IOTA Pharmaceuticals Limited
Statement of Financial Position
30 June 2024
2024
2023
Note
£
£
Current assets
Debtors
5
2,410
7,859
Cash at bank and in hand
15,009
100,499
--------
---------
17,419
108,358
Creditors: amounts falling due within one year
6
32,357
122,383
--------
---------
Net current liabilities
14,938
14,025
--------
--------
Total assets less current liabilities
( 14,938)
( 14,025)
--------
--------
Net liabilities
( 14,938)
( 14,025)
--------
--------
Capital and reserves
Called up share capital
350
350
Share premium account
7
49,496
49,496
Profit and loss account
7
( 64,784)
( 63,871)
--------
--------
Shareholders deficit
( 14,938)
( 14,025)
--------
--------
These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
For the year ending 30 June 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements were approved by the board of directors and authorised for issue on 4 December 2024 , and are signed on behalf of the board by:
D Bailey
P England
Director
Director
Company registration number: 06279987
IOTA Pharmaceuticals Limited
Notes to the Financial Statements
Year ended 30 June 2024
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is St Johns Innovation Centre, Cowley Road, Cambridge, Cambridgeshire, CB40WS, United Kingdom.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Foreign currencies
Foreign currency transactions are initially recorded in the functional currency, by applying the spot exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date, with any gains or losses being taken to the profit and loss account.
Government grants
Government grants are recognised at the fair value of the asset received or receivable. Grants are not recognised until there is reasonable assurance that the company will comply with the conditions attaching to them and the grants will be received.
Financial instruments
A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 3 (2023: 3 ).
5. Debtors
2024
2023
£
£
Other debtors
2,410
7,859
-------
-------
6. Creditors: amounts falling due within one year
2024
2023
£
£
Other creditors
32,357
122,383
--------
---------
7. Reserves
Profit and loss account - this reserve record retained earnings and accumulated losses.
8. Directors' advances, credits and guarantees
The company owed £5,738 to its director at year end; which is included within note "Creditors: amounts falling due within one year" (Other creditors).